Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: A multicentre registry in Turkey

Basit Öğe Kaydı
dc.authorscopusid6603145513
dc.authorscopusid58400264200
dc.authorscopusid58390172400
dc.authorscopusid7005791514
dc.authorscopusid35885183600
dc.authorscopusid55816023000
dc.authorscopusid8242042300
dc.contributor.authorZülfikar B.
dc.contributor.authorAydogan G.
dc.contributor.authorSalcioglu Z.
dc.contributor.authorOner A.F.
dc.contributor.authorKavakli K.
dc.contributor.authorGursel T.
dc.contributor.authorZülfikar H.
dc.date.accessioned2024-08-04T20:02:20Z
dc.date.available2024-08-04T20:02:20Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractLong used in established industrialized nations to treat patients with haemophilia and inhibitors, factor eight inhibitor bypassing activity (FEIBA) has, in recent years, been introduced into more geographically diverse settings. Data are needed on how successfully FEIBA therapy has been implemented in new regions. To determine the efficacy and safety of FEIBA for the treatment of acute bleeding and surgical haemostasis in a newly industrialized country. A multicentre registry of haemophilia A patients with inhibitors receiving FEIBA treatment was established in Turkey. With a standardized case report form, data were collected retrospectively on: patient demographics; characteristics of acute bleeding episodes and surgical interventions; FEIBA regimen; and treatment outcomes. Thirty-seven patients received a total of 112 FEIBA treatment courses, 90 for acute bleeding and 22 for surgical haemostasis. The median FEIBA dose per infusion for acute bleeding was 50IUkg -1, and for surgery was 100IUkg -1. For both acute joint and muscle/soft tissue bleeding and in surgery, haemostasis was attained in a median of two FEIBA infusions. FEIBA was judged effective in 92% of treatment courses for acute bleeding, with a 95% confidence interval (CI) of 85-97%. Rates of haemostatic efficacy did not differ significantly between anatomical sites of acute bleeding. The haemostatic efficacy rate of FEIBA in surgery was 86% (CI, 65-97%). No thromboembolic complications or other adverse events occurred during any treatment course. FEIBA has been successfully integrated into clinical practice in Turkey, with rates of haemostatic efficacy comparable to those reported in countries with a longer history of FEIBA usage. © 2011 Blackwell Publishing Ltd.en_US
dc.identifier.doi10.1111/j.1365-2516.2011.02693.x
dc.identifier.endpage391en_US
dc.identifier.issn1351-8216
dc.identifier.issue3en_US
dc.identifier.pmid22103429en_US
dc.identifier.scopus2-s2.0-84860324856en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage383en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2516.2011.02693.x
dc.identifier.urihttps://hdl.handle.net/11616/91620
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofHaemophiliaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute haemorrhageen_US
dc.subjectBlood coagulation factor inhibitorsen_US
dc.subjectFactor VIII inhibitor bypass activityen_US
dc.subjectHaemophilia Aen_US
dc.subjectHaemostatic efficacyen_US
dc.subjectSurgical haemostasisen_US
dc.titleEfficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: A multicentre registry in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu